Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 43,000
0
Funds holding %
of 6,805 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 243 | Existing positions closed: 162
11% more repeat investments, than reductions
Existing positions increased: 1,526 | Existing positions reduced: 1,370
2% more funds holding
Funds holding: 3,493 [Q2] → 3,574 (+81) [Q3]
1.67% less ownership
Funds ownership: 83.63% [Q2] → 81.96% (-1.67%) [Q3]
6% less capital invested
Capital invested by funds: $719B [Q2] → $677B (-$41.8B) [Q3]
12% less call options, than puts
Call options by funds: $9.13B | Put options by funds: $10.4B
15% less funds holding in top 10
Funds holding in top 10: 542 [Q2] → 460 (-82) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$885
12%
upside
Avg. target
$1,038
32%
upside
High target
$1,250
58%
upside
10 analyst ratings
10 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Tim Anderson 67% 1-year accuracy 4 / 6 met price target | 26%upside $997 | Buy Reinstated | 10 Dec 2024 |
Wolfe Research Alexandria Hammond 44% 1-year accuracy 4 / 9 met price target | 27%upside $1,000 | Outperform Initiated | 15 Nov 2024 |
Deutsche Bank James Shin 0% 1-year accuracy 0 / 4 met price target | 29%upside $1,015 | Buy Maintained | 4 Nov 2024 |
Barclays Carter Gould 38% 1-year accuracy 14 / 37 met price target | 24%upside $975 | Overweight Maintained | 31 Oct 2024 |
B of A Securities Geoff Meacham 44% 1-year accuracy 11 / 25 met price target | 39%upside $1,100 | Buy Maintained | 31 Oct 2024 |
Financial journalist opinion
Based on 113 articles about LLY published over the past 30 days
Neutral
PRNewsWire
1 day ago
Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion VIVID-1 was the first pivotal Crohn's disease trial to show benefits in hard-to-treat symptom of bowel urgency using a patient-centric scale Omvoh will be the first treatment for Crohn's disease with results demonstrating improvements of histologic measures of inflammation included in its label, if approved by the European Commission Lilly has also submitted Omvoh in the U.S. for approval to treat adults with moderately to severely active Crohn's disease, with a decision expected in the first half of 2025 INDIANAPOLIS , Dec. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh® (mirikizumab), an interleukin-23p19 (IL-23p19) antagonist, for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment. "I am excited for the potential of Omvoh as a novel treatment option for patients suffering from moderately to severely active Crohn's disease, since the majority of patients do not achieve remission on current therapies or cannot maintain it long term," said Stefan Schreiber, M.D.
Positive
Reuters
1 day ago
EMA says Lilly's weight-loss drug does not need separate approval for sleep apnea
The European Medicines Agency said on Friday Eli Lilly's weight-loss drug does not need a separate approval for the treatment of a sleep disorder called obstructive sleep apnea (OSA).
Positive
Reuters
1 day ago
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its European rival.
Positive
Zacks Investment Research
2 days ago
Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study
Data from a late-stage study shows that LLY's experimental oral drug benefited certain breast cancer patients when used as both a combination and monotherapy.
Neutral
Zacks Investment Research
2 days ago
3 Stocks to Keep an Eye on After Dividend Hike Announcement
Stocks like SYK, LLY and AES recently announced dividend hikes.
Positive
The Motley Fool
2 days ago
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly (LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its trailing earnings.
Negative
Zacks Investment Research
2 days ago
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.
Positive
Reuters
3 days ago
Telehealth firm Ro to provide single-dose vials of Lilly's Zepbound to obesity patients
Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity.
Neutral
PRNewsWire
3 days ago
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations As combination therapy, imlunestrant plus Verzenio significantly reduced the risk of progression or death by 43%, compared to imlunestrant alone, in all patients, regardless of ESR1 mutation status These data were published simultaneously in the New England Journal of Medicine and will be presented today at the 2024 San Antonio Breast Cancer Symposium INDIANAPOLIS , Dec. 11, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor. Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) as monotherapy in patients with an ESR1 mutation versus standard of care endocrine therapy (SOC ET), reducing the risk of disease progression or death by 38%.
Positive
CNBC
3 days ago
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
Direct-to-consumer health-care startup Ro said its platform will now offer more affordable single-dose vials of the weight loss drug Zepbound through a new partnership with Eli Lilly. Ro will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug delivered to their homes.
Charts implemented using Lightweight Charts™